-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18

Benzinga·08/10/2026 12:13:38
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.